AI could help lymphoma patients stick to their pills
NCT ID NCT07546188
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an artificial intelligence system designed to predict when lymphoma patients might not take their oral medications as prescribed. Researchers will enroll 210 adults with non-Hodgkin lymphoma and use AI to analyze patient data, aiming to catch non-compliance early. The goal is to improve care coordination and help doctors intervene before problems arise.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a tool that helps doctors spot when lymphoma patients are not taking their oral medications as prescribed, allowing for timely support.
- What could go wrong
- This is an early-stage quality improvement study with only 210 participants. The AI model may not perform well enough in real-world settings, and results may not apply to other cancers or hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 210 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients treated in the Haematology Department at Charleroi General Hospital for Non-Hodgkin lymphoma.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards * Treated for a lymphoma, Non Hodgkin * Capable of giving informed consent Exclusion Criteria: * All other patients who did not meet the eligibility criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Care coordination are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Grand Hôpital de Charleroi
RECRUITINGCharleroi, Hainaut, 6060, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Nine-Week group program help blood cancer patients grow through trauma?
- Which lymphoma drug combo works best? a new study aims to find out
- Can a Nurse-Led plan smooth the Hospital-to-Home journey for complex kids?
- Can a single shot build a cancer army inside the body?
- Rare childhood bone lymphoma: can past cases guide future care?
- New pill targets Hard-to-Treat lymphoma in early human test